Myricx Pharma Ltd announced that it has received £90 million in a round of funding co-led by new investors Novo Holdings A/S and Abingworth LLP on July 8, 2024. The transaction included participation from new investors Cancer Research Horizons, Cancer Research Horizons, Eli Lilly and Company, returning investors Brandon Capital Partners and Sofinnova Partners SAS. Michael Bauer from Novo Holdings A/S and Lucille Conroy from Abingworth LLP will join board of directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
950.5 USD | +0.24% |
|
+3.54% | +63.05% |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
12/07 | Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,794 DKK | -0.80% | +1.84% | 1.68TCr | ||
950.5 USD | +0.24% | +3.54% | 86TCr | ||
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.05% | 86TCr | |
+39.09% | 63TCr | |
-4.78% | 36TCr | |
+17.52% | 32TCr | |
+8.43% | 30TCr | |
+13.62% | 24TCr | |
+5.19% | 23TCr | |
+16.32% | 23TCr | |
+14.63% | 18TCr | |
+1.08% | 16TCr |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Myricx Pharma Ltd announced that it has received £90 million in funding from a group of investors